Compare Gilead Sciences, Inc. (GILD) vs Toyota Motor Corp (TM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Toyota Motor Corp — how do they compare? Gilead Sciences, Inc. trades at $151.17 (market cap $182.40B), while Toyota Motor Corp trades at $185.3 (market cap $217.38B). The key difference: Toyota Motor Corp is the larger of the two by market cap, and Toyota Motor Corp pays the higher dividend (3.37%). Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and Toyota Motor Corp for 116 Days on average.
| GILD | TM | |
|---|---|---|
Market Cap | $182.40B | $217.38B |
Volume | 4,469,821 | 291,250 |
Sector | Health | Consumer Cyclical |
52-Week High | $155.80 | $248.29 |
52-Week Low | $116.74 | $166.50 |
Typical Hold Time | 111 Days | 116 Days |
Enterprise Value | $205.46B | $410.96B |
Dividend Yield | 2.23% | 3.37% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $151.17, up 2.94% recently, with strong technical momentum and bullish moving averages. The company shows robust revenue growth to $29.44B in 2025 and beat earnings estimates in three consecutive quarters, though net income margin turned negative at -10.64% for 2026. Recent developments include expanded HIV drug access in Latin America via a PAHO partnership, positioning Gilead for growth in its core franchises.
Gilead presents a mixed outlook with solid operational cash flow and analyst bullishness (65.5% buy ratings) offset by profitability concerns and high debt levels. The stock's current price aligns with the consensus target of $151.57, suggesting limited near-term upside. Key risks include execution in oncology pipeline expansion and reliance on HIV treatment revenues amid competitive pressures.
Toyota Motor trades at $185.30, up 1.31% with bearish technical signals despite strong fundamentals. The stock shows attractive valuation metrics with P/E of 8.38 and P/B of 0.93, while maintaining solid profitability with 8.63% net margin and 12.23% ROE. Recent earnings beats and expanding electrified vehicle sales (37.8% growth in September 2026) support the investment case, though technical indicators suggest near-term pressure.
Toyota presents a value opportunity with strong cash generation and market leadership, but faces headwinds from China sales declines and production disruptions. Analyst consensus leans cautious with 62.5% hold ratings, reflecting concerns about profit margin compression and competitive pressures in key markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Toyota Motor Corp
Founded in 1937, Toyota is one of the world's largest automakers with 10.38 million units sold at retail in fiscal 2022 across its light vehicle brands. Brands include Toyota, Lexus, Daihatsu, and truck maker Hino.
Read more on TM →
